Skip to main content
. 2015 Oct 29;6:248. doi: 10.3389/fphar.2015.00248

Table 6.

Energy decomposition of predicted ΔEbinding.

anti-VEGF Favorable contributions of residues in anti-VEGF binding domain
Ranibizumab Thr 105 (−56), Tyr 101 (−115), His 31(−129)
Fab-bevacizumab Ser 105 (−44), His 101 (−82), Asn 31 (−22)
VEGFR1d2_R2d3 Arg 154 (−171), Lys 157 (−190), Lys 165(−157), Lys 166 (−129), Arg 128 (−123), Lys 72 (−112), Lys 43 (−118), Lys 89 (−93), Arg 96 (−167)

Values in brackets correspond to energy contribution of the residues (KJ/mol).